AVXL SEC-Einreichungen - Anavex Life Sciences Corp.- Jahresbericht, Proxy Statement, Prospekt

Basisstatistiken

LEI	549300K1I5L8COCQ8W36
CIK	1314052

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Anavex Life Sciences Corp.

SEC Filings (Chronological Order)

Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.

May 22, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2026 ANAVEX LIFE SCIENCES UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2026 ANAVEX LIFE SCIENCES CORP. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37606 98-0608404 (State or Other Jurisdiction of Incorporation) (Commission F
May 22, 2026	EX-99.1	Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification Exhibit 99.1 Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification NEW YORK, NY, May 22, 2026 - Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, today announced it received an expected delinquency notification letter (the “Notice”
May 15, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2026 ANAVEX LIFE SCIENCES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2026 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of in
May 11, 2026	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2026 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on F
May 6, 2026	EX-99.1	Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer EXHIBIT 99.1 Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer NEW YORK, NY, May 6, 2026 - Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s dise
May 6, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2026 ANAVEX LIFE SCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2026 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of
March 25, 2026	EX-99.1	Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease EXHIBIT 99.1 Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease NEW YORK – March 25, 2026 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental,
March 25, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2026 ANAVEX LIFE SCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2026 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of
February 25, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2026 ANAVEX LIFE SCI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2026 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer
February 25, 2026	EX-99.1	Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors EXHIBIT 99.1 Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors NEW YORK – February 23, 2026 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases,
February 9, 2026	EX-99.1	Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update Company to host a webcast today at 8:30 am Eastern Time EXHIBIT 99.1 Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update Company to host a webcast today at 8:30 am Eastern Time NEW YORK – February 9, 2026 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s dise
February 9, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX L
February 9, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2026 ANAVEX LIFE SCIE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2026 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer o
November 25, 2025	EX-99.1	Press Release of the Company dated November 25, 2025 EXHIBIT 99.1 Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK – November 25, 2025 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s
November 25, 2025	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Incorporation or Organization Anavex Australia Pty Limited Australia Anavex Germany GmbH Germany Anavex Canada Ltd. Ontario, Canada
November 25, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37606 ANAVEX LIFE SCIE
November 25, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2025 ANAVEX LIFE SCI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2025 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer
November 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2025 ANAVEX LIFE SCIEN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2025 ANAVEX LIFE SCIENCES CORP.
November 14, 2025	EX-99.1	Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease Company plans to request re-examination after CHMP opinion feedback following its oral explanation FDA advises Company to meet and discuss Company’s Alzheim EXHIBIT 99.1 Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease Company plans to request re-examination after CHMP opinion feedback following its oral explanation FDA advises Company to meet and discuss Company’s Alzheimer's Disease clinical trial results NEW YORK – November 14, 2025 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL),
August 12, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE
July 28, 2025	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of i
July 28, 2025	EX-1.1	Sales Agreement, dated July 25, 2025, by and between Anavex Life Sciences Corp. and TD Securities (USA) LLC EXHIBIT 1.1 Anavex Life Sciences Corp. COMMON STOCK SALES AGREEMENT July 25, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Anavex Life Sciences Corp., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from ti
July 25, 2025	424B5	Anavex Life Sciences Corp. Up to $150,000,000 of Common Stock As Filed Pursuant to Rule 424(b)(5) Registration No. 333-288661 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 23, 2025) Anavex Life Sciences Corp. Up to $150,000,000 of Common Stock On July 25, 2025, we entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA) LLC (“TD Cowen”), relating to the sale of shares of our common stock, par value $0.001 per share, from time to time
July 21, 2025	CORRESP	ANAVEX LIFE SCIENCES CORP. 630 5th Avenue, 20th Floor New York, NY USA 10111 ANAVEX LIFE SCIENCES CORP. 630 5th Avenue, 20th Floor New York, NY USA 10111 July 21, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Attn: Jessica Dickerson Re: Anavex Life Sciences Corp. Request for Acceleration of Registration Statement on Form S-3 File No. 333-288661 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of
July 21, 2025	CORRESP	ANAVEX LIFE SCIENCES CORP. 630 5th Avenue, 20th Floor New York, NY USA 10111 ANAVEX LIFE SCIENCES CORP. 630 5th Avenue, 20th Floor New York, NY USA 10111 July 21, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Attn: Jessica Dickerson Re: Anavex Life Sciences Corp. Request for Acceleration of Registration Statement on Form S-3 File No. 333-288661 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of
July 21, 2025	LETTER	LETTER July 21, 2025 Christopher Missling Chief Executive Officer Anavex Life Sciences Corp.
July 14, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Anavex Life Sciences Corp.
July 14, 2025	S-3	As filed with the Securities and Exchange Commission on July 14, 2025 As filed with the Securities and Exchange Commission on July 14, 2025 Registration No.
July 3, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2025 ANAVEX LIFE SCIENCES C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2025 ANAVEX LIFE SCIENCES CORP.
July 3, 2025	EX-10.1	Fourth Amendment to Employment Agreement by and between Anavex Life Sciences Corp. and Christopher Missling, PhD, dated July 3, 2025 EXHIBIT 10.1 FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT This Fourth Amendment to Employment Agreement (this “Amendment”) is executed on this 3rd day of July 2025, and made effective as defined below (the “Effective Date”), by and between Christopher Missling, PhD (hereinafter referred to as “Executive”) and Anavex Life Sciences Corp. (“Employer” and, together with its subsidiaries, the “Company”) an
July 3, 2025	EX-10.2	Third Amendment to Employment Agreement by and between Anavex Life Sciences Corp. and Sandra Boenisch, dated July 3, 2025 EXHIBIT 10.2 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This Third Amendment to Employment Agreement (the “Amendment”) is executed on this July 3, 2025 (the “Effective Date”), by and between Sandra Boenisch (hereinafter referred to as “Employee”) and Anavex Life Sciences Corp. (together with its subsidiaries, the “Company”). Employee and Company are collectively referred to as the “Parties” and singu
June 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 ANAVEX LIFE SCIENCE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of i
June 13, 2025	EX-10.1	Amendment No. 1 to Anavex Life Sciences Corp. 2022 Omnibus Incentive Plan, as approved by the Company’s stockholders on June 10, 2025 EXHIBIT 10.1 AMENDMENT NO. 1 TO ANAVEX LIFE SCIENCES CORP. 2022 OMNIBUS INCENTIVE PLAN The Anavex Life Sciences Corp. 2022 Omnibus Incentive Plan (the “Plan”) is hereby amended as follows (capitalized terms used herein and not defined herein shall have the respective meaning ascribed to such terms in the Plan): 1. Section 3 of the Plan shall be amended by adding the following new Section 3.7 immed
May 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE
April 25, 2025	ARS	ARS 2024 Annual Reporti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 25, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of
April 25, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of
February 12, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX L
December 23, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37606 ANAVEX LIFE SCIE
December 23, 2024	EX-21.1	Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Incorporation or Organization Anavex Australia Pty Limited Australia Anavex Germany GmbH Germany Anavex Canada Ltd. Ontario, Canada
December 23, 2024	EX-19.1	Insider Trading Policy EXHIBIT 19.1 ANAVEX LIFE SCIENCES CORP. Insider Trading Policy Anavex Life Sciences Corp. (“Anavex”) has adopted this Insider Trading Policy (the “Policy”) to promote compliance with federal securities laws by directors, officers, employees and consultants of Anavex and its affiliates, as well as any immediate family members sharing the household of any of the foregoing (collectively, the “Covered
August 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE
July 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 ANAVEX LIFE SCIENCE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of i
July 29, 2024	S-3	As filed with the Securities and Exchange Commission on July 29, 2024 As filed with the Securities and Exchange Commission on July 29, 2024 Registration No.
July 29, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Anavex Life Sciences Corp.
June 21, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 ANAVEX LIFE SCIENCE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of i
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE
May 9, 2024	EX-99.1	Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update Company to host a webcast today at 8:30 a.m. Eastern Time EXHIBIT 99.1 Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK – May 9, 2024 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodev
May 9, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 ANAVEX LIFE SCIENCES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of inc
May 6, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of
May 6, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of
February 13, 2024	SC 13G/A	AVXL / Anavex Life Sciences Corp. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Anavex Life Sciences Corp Title of Class of Securities: Common Stock CUSIP Number: 032797300 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is fi
February 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX L
January 25, 2024	SC 13G/A	AVXL / Anavex Life Sciences Corp. / BlackRock Inc. Passive Investment us0327973006012524.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) ANAVEX LIFE SCIENCES CORP. - (Name of Issuer) Common Stock - (Title of Class of Securities) 032797300 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur
January 22, 2024	SC 13G/A	AVXL / Anavex Life Sciences Corp. / STATE STREET CORP Passive Investment SC 13G/A 1 AnavexLifeScCorp.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING ANAVEX LIFE SCIENCES CORP (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 032797300 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PU
November 27, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37606 ANAVEX LIFE SCIE
November 27, 2023	EX-14.1	Code of Ethics Adopted on August 1, 2023 EXHIBIT 14.1 BUSINESS CODE OF CONDUCT & ETHICS I. INTRODUCTION/PURPOSE As a business engaged in the discovery, development and commercialization of medicines for the treatment of various diseases, AnavexTM Life Sciences Corp. (the “Anavex” or the “Company”) must always act in a way that reflects the highest standards of corporate behavior and conduct itself in a legal and ethical manner. Each of u
November 27, 2023	EX-97.1	Anavex Life Sciences Corp. Compensation Clawback Policy* EXHIBIT 97.1 ANAVEX LIFE SCIENCES CORP. NASDAQ RULE 5608 EXECUTIVE OFFICER COMPENSATION CLAWBACK Policy Effective NOVEMBER 8, 2023 1. Policy Purpose. The purpose of this Anavex Life Sciences Corp. Nasdaq Rule 5608 Executive Officer Compensation Clawback Policy (this “Policy”) is to enable Anavex Life Sciences Corp. and its subsidiaries and affiliates (the “Company”) to recover Erroneously Awarded
November 27, 2023	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Incorporation or Organization Anavex Australia Pty Limited Australia Anavex Germany GmbH Germany Anavex Canada Ltd. Ontario, Canada
August 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE
May 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 ANAVEX LIFE SCIENCES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of in
May 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE
April 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2023 ANAVEX LIFE SCIENCES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2023 ANAVEX LIFE SCIENCES CORP.
April 14, 2023	EX-3.1	Amended and Restated Bylaws (incorporated by reference to our Current Report on Form 8-K filed on April 14, 2023) EXHIBIT 3.1 AMENDED AND RESTATED BYLAWS OF ANAVEX LIFE SCIENCES CORP. A Nevada Corporation ARTICLE I STOCKHOLDERS SECTION 1 Annual Meeting. Annual meetings of the stockholders of Anavex Life Sciences Corp. (the “Corporation”), shall be held on the day and at the time as may be set by the Board of Directors of the Corporation (the “Board of Directors”) from time to time, at which annual meeting the
April 4, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of
April 4, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of
March 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 ANAVEX LIFE SCIENCES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 ANAVEX LIFE SCIENCES CORP.
February 9, 2023	SC 13G/A	AVXL / Anavex Life Sciences Corp / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMEMDED FILING ANAVEX LIFE SCIENCES CORP (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 032797300 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE
February 9, 2023	SC 13G/A	AVXL / Anavex Life Sciences Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Anavex Life Sciences Corp. Title of Class of Securities: Common Stock CUSIP Number: 032797300 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is f
February 7, 2023	EX-FILING FEES	Calculation of Filing Fee Table Form 424(b)(5) (Form Type) ANAVEX LIFE SCIENCES CORP. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities EX-FILING FEES 2 e4391ex107.htm EXHIBIT 107 Exhibit 107 Calculation of Filing Fee Table Form 424(b)(5) (Form Type) ANAVEX LIFE SCIENCES CORP. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering price
February 7, 2023	424B5	Anavex Life Sciences Corp. Up to $150,000,000 of Common Stock and Up to 150,000 Shares of Common Stock as Commitment Shares PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated September 24, 2021) Registration No.
February 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 ANAVEX LIFE SCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 ANAVEX LIFE SCIENCES CORP.
February 7, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX L
February 7, 2023	EX-4.1	Registration Rights Agreement, dated February 3, 2023, by and between the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 4.1 to our Quarterly Report on Form 10-Q for the period ended December 31, 2022 filed on February 7, 2023) EXHIBIT 4.1 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 3, 2023 by and between ANAVEX LIFE SCIENCES CORP., a Nevada corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall hav
February 7, 2023	EX-10.1	Purchase Agreement dated February 3, 2023 by and between the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the period ended December 31, 2022 filed on February 7, 2023) EXHIBIT 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated as of February 3, 2023 by and between ANAVEX LIFE SCIENCES CORP., a Nevada corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). Capitalized terms used herein and not otherwise defined herein are defined in Section 1 hereof. WHEREAS: Subject to the ter
January 31, 2023	SC 13G/A	AVXL / Anavex Life Sciences Corp / BlackRock Inc. Passive Investment us0327973006013123.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) ANAVEX LIFE SCIENCES CORP - (Name of Issuer) Common Stock - (Title of Class of Securities) 032797300 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs
January 27, 2023	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3760
December 2, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 ANAVEX LIFE SCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 ANAVEX LIFE SCIENCES CORP.
December 2, 2022	EX-99.1	ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS, SHOWING STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN GLOBAL CLINICAL STUDY OF PATIENTS WITH EARLY ALZHEIMER’S DISEASE EXHIBIT 99.1 ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS, SHOWING STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN GLOBAL CLINICAL STUDY OF PATIENTS WITH EARLY ALZHEIMER’S DISEASE ● Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADL ● Key Secondary Endpoint CDR
November 28, 2022	EX-4.1	Description of Registrant’s Securities (incorporated by reference to our Annual Report on Form 10-K filed on November 28, 2022) EXHIBIT 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Anavex Life Sciences Corp (the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: the Company?s common stock, par value $0.001 per share (the ?Common Stock?) Description of Common Stock The following summ
November 28, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37606 ANAVEX LIFE SCIE
August 12, 2022	LETTER	LETTER United States securities and exchange commission logo August 12, 2022 Sandra Boenisch Principal Financial Officer ANAVEX LIFE SCIENCES CORP.
August 10, 2022	CORRESP	ANAVEX LIFE SCIENCES CORP. 630 5th Avenue, 20th Floor New York, NY 10111 August 10, 2022 ANAVEX LIFE SCIENCES CORP. 630 5th Avenue, 20th Floor New York, NY 10111 August 10, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, DC 20549 Attention: Jeanne Baker Terence O?Brien Re: Anavex Life Sciences Corp. Form 10-K for Fiscal Year Ended September 30, 2021 Filed November 24, 2021 File No. 001-37606 Dear Ms. Baker
August 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE
July 29, 2022	LETTER	LETTER United States securities and exchange commission logo July 29, 2022 Sandra Boenisch Principal Financial Officer ANAVEX LIFE SCIENCES CORP.
June 10, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES 4 e3822ex107.htm EXHIBIT 107 Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Anavex Life Sciences Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of R
June 10, 2022	S-8	As filed with the Securities and Exchange Commission on June 10, 2022 As filed with the Securities and Exchange Commission on June 10, 2022 Registration No.
May 27, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of in
May 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE
April 11, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of
April 11, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of
April 8, 2022	EX-10.1	Third Amendment to Employment Agreement, dated April 7, 2022 by and between the Company and Christopher Missling, PhD (incorporated by reference to our Current Report on Form 8-K filed on April 8, 2022) EXHIBIT 10.1 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This Third Amendment to Employment Agreement (this ?Amendment?) is executed on this seventh day of April 2022, and made effective as defined below (the ?Effective Date?), by and between Christopher Missling, PhD (hereinafter referred to as ?Executive?) and Anavex Life Sciences Corp. (?Employer? and, together with its subsidiaries, the ?Company?)
April 8, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2022 ANAVEX LIFE SCIENCES CORP.
March 4, 2022	EX-99.1	Anavex Life Sciences Announces Change of Auditor to Grant Thornton LLP EXHIBIT 99.1 Anavex Life Sciences Announces Change of Auditor to Grant Thornton LLP NEW YORK ? March 4, 2022 ? Anavex Life Sciences Corp. (?Anavex? or the ?Company?) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer?s disease, Parkinson?s disease, Rett syndrom
March 4, 2022	EX-16.1	Letter from BDO USA LLP to the Securities and Exchange Commission dated March 4, 2022 EXHIBIT 16.1 March 4, 2022 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on March 1, 2022, to be filed by our former client, Anavex Life Sciences Corp.. We agree with the statements made in response to that Item insofar as they relate to our Firm. Very truly yours,
March 4, 2022	EX-10.1	Amendment No. 2 to Amended and Restated Employment Agreement between the Company and Sandra Boenisch, dated February 28, 2022 Exhibit 10.1 AMENDMENT NO. 2 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 2 (the ?Amendment?) to the Amended and Restated Employment Agreement, dated October 4, 2017 (the ?Employment Agreement?) is dated February 28, 2022 with an effective date of March 1, 2022, is by and between Anavex Life Sciences Corp. (the ?Company? or ?Anavex?), and Sandra Boenisch (the ?Employee?). Except
March 4, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2022 ANAVEX LIFE SCIENCES CORP.
February 9, 2022	SC 13G	AVXL / Anavex Life Sciences Corp / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv0263-anavexlifesciencescor.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Anavex Life Sciences Corp. Title of Class of Securities: Common Stock CUSIP Number: 032797300 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule p
February 9, 2022	SC 13G	AVXL / Anavex Life Sciences Corp / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INITIAL FILING ANAVEX LIFE SCIENCES CORP (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 032797300 (CUSIP NUMBER) 12/31/2021 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE
February 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX L
February 4, 2022	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2022 ANAVEX LIFE SCIENCES CORP.
February 4, 2022	EX-99.1	Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome EXHIBIT 99.1 Anavex Life Sciences Provides Supplemental Information on ANAVEX?2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome NEW YORK ? February 4, 2022 ? Anavex Life Sciences Corp. (?Anavex? or the ?Company?) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and
February 3, 2022	SC 13G/A	AVXL / Anavex Life Sciences Corp / BlackRock Inc. Passive Investment us0327973006020222.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) ANAVEX LIFE SCIENCES CORP - (Name of Issuer) Common Stock - (Title of Class of Securities) 032797300 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs
February 2, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2022 ANAVEX LIFE SCIENCES CORP.
February 2, 2022	EX-99.1	Furnished herewith EXHIBIT 99.1
November 24, 2021	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Incorporation or Organization Anavex Australia Pty Limited Australia Anavex Germany GmbH Germany Anavex Canada Ltd. Ontario, Canada
November 24, 2021	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37606 ANAVEX LIFE SCIE
November 24, 2021	EX-3.1	Articles of Incorporation (incorporated by reference to Exhibit 3.1 to our Annual Report on Form 10-K for the year ended September 30, 2021 filed on November 24, 2021) Exhibit 3.1
September 27, 2021	EX-99.1	Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market® Exhibit 99.1 Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market? NEW YORK ? September 27, 2021 ? Anavex Life Sciences Corp. (?Anavex? or the ?Company?) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer?s disease, Parkinson?s disease, R
September 27, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2021 ANAVEX LIFE SCIENCES CORP.
September 24, 2021	S-3ASR	As filed with the Securities and Exchange Commission on September 24, 2021 As filed with the Securities and Exchange Commission on September 24, 2021 Registration No.
September 13, 2021	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 ANAVEX LIFE SCIE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 ANAVEX LIFE SCIENCES CORP.
September 13, 2021	EX-99.1	Investor Presentation EXHIBIT 99.1
August 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE
June 24, 2021	424B5	Anavex Life Sciences Corp. 2,380,953 Shares of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated July 15, 2019) Registration No.
June 24, 2021	EX-10.2	Form of Securities Purchase Agreement dated June 22, 2021, between Anavex Life Sciences Corp. and the investor named therein Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of June 22, 2021, between Anavex Life Sciences Corp., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions
June 24, 2021	EX-10.1	Letter Agreement, dated June 22, 2021 between Anavex Life Sciences Corp. and H.C. Wainwright & Co., LLC Exhibit 10.1 Execution Version June 21, 2021 STRICTLY CONFIDENTIAL Anavex Life Sciences Corp. 51 West 52nd Street, 7th Floor New York, NY 10019 Attn: Christopher Missling, Ph.D., Chief Executive Officer Dear Dr. Missling: This letter agreement (this ?Agreement?) constitutes the agreement between Anavex Life Sciences Corp. (the ?Company?) and H.C. Wainwright & Co., LLC (?Wainwright?), that Wainwrig
June 24, 2021	EX-99.1	Anavex Life Sciences Announces $50 Million Registered Direct Offering Exhibit 99.1 Anavex Life Sciences Announces $50 Million Registered Direct Offering NEW YORK ? June 22, 2021 ? Anavex Life Sciences Corp. (?Anavex? or the ?Company?) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer?s disease, Parkinson?s disease, Rett syndrome
June 24, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2021 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of i
May 28, 2021	EX-3.1	Certificate of Amendment to Articles of Incorporation (incorporated by reference to our Current Report on Form 8-K filed on May 28, 2021) Exhibit 3.1
May 28, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2021 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of in
May 13, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE
April 12, 2021	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of
April 9, 2021	S-8	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 98-0608404 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification Number) 51 West 52nd Street, 7th Floor New York, NY 10019-6163 Telephon
April 1, 2021	PRE 14A	- PRELIMINARY INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of
February 16, 2021	424B5	Anavex Life Sciences Corp. Up to $50,000,000 Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated July 15, 2019) Registration No.
February 16, 2021	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX L
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* ANAVEX LIFE SCIENCES CORP. (Name of Issuer) Common Stock, PAR VALUE $0.001 per share (Title of Class of Securities) 032797300 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
February 2, 2021	SC 13G	SC 13G us0327973006020221.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) ANAVEX LIFE SCIENCES CORP - (Name of Issuer) Common Stock - (Title of Class of Securities) 032797300 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu
December 28, 2020	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Incorporation or Organization Anavex Australia Pty Limited Australia Anavex Germany GmbH Germany Anavex Canada Ltd. Ontario, Canada
December 28, 2020	EX-99.1	Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates Conference Call and Webcast Today at 4:30 p.m. ET Exhibit 99.1 Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates Conference Call and Webcast Today at 4:30 p.m. ET NEW YORK – December 28, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopm
December 28, 2020	10-K	Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37606 ANAVEX LIFE SCIE
December 28, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2020 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer
December 15, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2020 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer
December 15, 2020	EX-99.1	Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome Primary safety, pharmacokinetics and secondary ef Exhibit 99.1 Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome Primary safety, pharmacokinetics and secondary efficacy endpoints met, with consistent improvements in RSBQ Total scores and CGI-I Efficacy endpoints demonstrated statistically significa
November 6, 2020	EX-99.2	Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 Conference Statistically significant improvements in CDR system Cognitive Domain of Attention assesse Exhibit 99.1 Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 Conference Statistically significant improvements in CDR system Cognitive Domain of Attention assessed by Choice Reaction Time (p = 0.039) and Digital Vigilance (p = 0.008) Statistically significant dose-dependent improvements in Episodic
November 6, 2020	8-K	Other Events, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2020 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer o
November 6, 2020	EX-99.2	The Presentation dated November 6, 2020 Exhibit 99.2
October 15, 2020	EX-99.1	Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Clinically meaningful, dose-dependent, and statistically significant improve Exhibit 99.1 Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Clinically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis Company to host conference call today at 8:30 AM ET NE
October 15, 2020	8-K	Regulation FD Disclosure, Other Events, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2020 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer o
August 6, 2020	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE
July 2, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2020 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of in
July 2, 2020	424B5	Anavex Life Sciences Corp. Up to $25,272,213 Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated July 15, 2019) Registration No.
July 2, 2020	EX-10.1	First Amendment to Purchase Agreement, dated as of July 1, 2020, by and between the Company and Lincoln Park Capital Fund, LLC Exhibit 10.1 FIRST AMENDMENT TO PURCHASE AGREEMENT THIS FIRST AMENDMENT TO PURCHASE AGREEMENT (this “First Amendment”), dated as of July 1, 2020, by and between ANAVEX LIFE SCIENCES CORP., a Nevada corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS, the Company and the Investor entered into that certain Purchase Agreemen
May 7, 2020	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE
May 1, 2020	8-K	Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2020 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of inc
May 1, 2020	424B5	Anavex Life Sciences Corp. Up to $30,331,854 Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated July 15, 2019) Registration No.
May 1, 2020	EX-1.1	Amended and Restated Sales Agreement, dated May 1, 2020, by and among the Company, Cantor Fitzgerald & Co. and SVB Leerink LLC (incorporated by reference to our Current Report on Form 8-K filed on May 1, 2020) Exhibit 1.1 ANAVEX LIFE SCIENCES CORP. Shares of Common Stock (par value $0.001 per share) Amended and Restated Sales Agreement May 1, 2020 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 SVB Leerink LLC 1301 Avenue of the Americas, 12th Floor New York, NY 10019 Ladies and Gentlemen: Reference is made to the Controlled Equity OfferingSM Sales Agreement, dated as of July 6, 2018 (the “Or
May 1, 2020	424B5	Anavex Life Sciences Corp. Up to $50,000,000 Common Stock 424B5 1 e1888424b5.htm 424B5 PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated July 15, 2019) Registration No. 333-232550 Anavex Life Sciences Corp. Up to $50,000,000 Common Stock On May 1 2020, we entered into an amended and restated sales agreement, or the Sales Agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, and SVB Leerink LLC, or SVB Leerink, and toget
April 8, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2020 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of i
March 23, 2020	DEFA14A	AVXL / Anavex Life Sciences Corp. DEFA14A - - DEFA14A DEFA14A 1 e1821defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, For Use of the Commission Only
March 9, 2020	SC 13G/A	AVXL / Anavex Life Sciences Corp. / BlackRock Inc. Passive Investment us0327973006030920.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) ANAVEX LIFE SCIENCES CORP - (Name of Issuer) Common Stock - (Title of Class of Securities) 032797300 - (CUSIP Number) February 29, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs
February 20, 2020	DEF 14A	Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, Fo
February 14, 2020	SC 13G/A	AVXL / Anavex Life Sciences Corp. / Park West Asset Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ANAVEX LIFE SCIENCES CORP. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 032797300 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
February 7, 2020	SC 13G	AVXL / Anavex Life Sciences Corp. / BlackRock Inc. Passive Investment us0327973006020620.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) ANAVEX LIFE SCIENCES CORP - (Name of Issuer) Common Stock - (Title of Class of Securities) 032797300 - (CUSIP Number) December 31, 2019 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu
February 6, 2020	10-Q	Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAV
February 6, 2020	EX-10.1	Amendment No. 1 to Amended and Restated Employment Agreement between the Company and Sandra Boenisch, dated February 4, 2020 (incorporated by reference to our Quarterly Report on Form 10-Q filed on February 6, 2020) Exhibit 10.1 AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 1 (the “Amendment”) to the Amended and Restated Employment Agreement, dated October 4, 2017 (the “Employment Agreement”) is dated February 4, 2020 with an effective date of March 1, 2020, is by and between Anavex Life Sciences Corp. (the “Company” or “Anavex”), and Sandra Boenisch (the “Employee”). Except
December 16, 2019	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Incorporation or Organization Anavex Australia Pty Limited Australia Anavex Germany GmbH Germany Anavex Canada Ltd. Ontario, Canada
December 16, 2019	10-K	AVXL / Anavex Life Sciences Corp. 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37606 ANAVEX LIFE SCIE
September 17, 2019	POS AM	AVXL / Anavex Life Sciences Corp. POS AM - - FORM POS AM As filed with the Securities and Exchange Commission on September 17, 2019 Registration No.
September 16, 2019	AW	AVXL / Anavex Life Sciences Corp. AW - - AW AW 1 aw091619anavexlife.htm AW ANAVEX LIFE SCIENCES CORP. 51 W. 52nd Street, 7th Floor New York, NY 10019-6163 September 16, 2019 VIA EDGAR United States Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Anavex Life Sciences Corp. Form AW - Request for Withdrawal Amendment No. 4 to Registration Statement on Form S-3 File No. 333-207600 Ladies and Gentlemen: Pursuant t
September 13, 2019	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2019 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer
September 13, 2019	424B5	Anavex Life Sciences Corp. Up to $15,514,532 of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated July 15, 2019) Registration No.
September 13, 2019	S-3/A	AVXL / Anavex Life Sciences Corp. S-3/A - - AMENDMENT NO. 4 TO FORM S-3 As filed with the Securities and Exchange Commission on September 13, 2019 Registration No.
August 7, 2019	10-Q	June 30, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE
July 12, 2019	CORRESP	AVXL / Anavex Life Sciences Corp. CORRESP - - ANAVEX LIFE SCIENCES CORP. 51 W. 52nd Street, 7th Floor New York, NY 10019-6163 July 12, 2019 VIA EDGAR United States Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Attn: Michael Killoy Re: Anavex Life Sciences Corp. Request for Acceleration of Registration Statement on Form S-3 File No. 333-232550 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of
July 11, 2019	LETTER	LETTER July 11, 2019 Christopher Missling Chief Executive Officer Anavex Life Sciences Corp.
July 11, 2019	TEXT-EXTRACT	AVXL / Anavex Life Sciences Corp. TEXT-EXTRACT - - July 11, 2019 Christopher Missling Chief Executive Officer Anavex Life Sciences Corp.
July 3, 2019	S-3	AVXL / Anavex Life Sciences Corp. S-3 - - REGISTRATION STATEMENT S-3 1 fs32019anavexlifesciences.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on July 3, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 98-0608404 (State or oth
June 12, 2019	424B5	Anavex Life Sciences Corp. Up to $21,159,993 Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated September 6, 2016) Registration No.
June 12, 2019	EX-10.1	Purchase Agreement, dated as of June 7, 2019, by and between the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to our Current Report on Form 8-K filed on June 12, 2019) Exhibit 10.1 EXECUTION VERSION PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated as of June 7, 2019, by and between ANAVEX LIFE SCIENCES CORP., a Nevada corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). Capitalized terms used herein and not otherwise defined herein are defined in Section 1 hereof. WHEREAS: Sub
June 12, 2019	EX-4.1	Registration Rights Agreement, dated as of June 7, 2019, by and between the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to our Current Report on Form 8-K filed on June 12, 2019) Exhibit 4.1 Execution Version Registration Rights Agreement REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 7, 2019 by and between ANAVEX LIFE SCIENCES CORP., a Nevada corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined her
June 12, 2019	8-K	Financial Statements and Exhibits, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2019 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission File Number) (IRS E
May 9, 2019	EX-10.1	Second Amendment to Employment Agreement, dated as of May 3, 2019 by and between the Company and Christopher Missling, PhD (incorporated by reference to our Quarterly Report on Form 10-Q filed on May 9, 2019) Exhibit 10.1 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement (the “Amendment”) is executed on this 3rd day of May 2019 (the “Effective Date”), by and between Christopher Missling, PhD (hereinafter referred to as “Executive”) and Anavex Life Sciences Corp. (“Employer” and, together with its subsidiaries, the “Company”) and serves to amend that certain Employme
May 9, 2019	EX-3.1	Articles of Incorporation (incorporated by reference to Exhibit 3.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed on May 9, 2019) Exhibit 3.1
May 9, 2019	10-Q	March 31, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE
April 8, 2019	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2019 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of i
March 18, 2019	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2019 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of
March 16, 2019	424B5	Anavex Life Sciences Corp. Up to $9,711,390 Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated September 6, 2016) Registration No.
February 14, 2019	SC 13G/A	AVXL / Anavex Life Sciences Corp. / Park West Asset Management LLC - ANAVEX LIFE AMENDMENT NO. 2 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ANAVEX LIFE SCIENCES CORP. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 032797300 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
February 11, 2019	DEF 14A	Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of
February 7, 2019	10-Q	December 31, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX L
January 31, 2019	PRE 14A	AVXL / Anavex Life Sciences Corp. PRE 14A PRE 14A 1 s115426pre14a.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy
January 25, 2019	10-K/A	Form 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3760
December 12, 2018	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Incorporation or Organization Anavex Australia Pty Limited Australia Anavex Germany GmbH Germany Anavex Canada Ltd. Ontario, Canada
December 12, 2018	10-K	Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37606 ANAVEX LIFE SCIE
August 9, 2018	10-Q	AVXL / Anavex Life Sciences Corp. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE
July 6, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2018 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of in
July 6, 2018	EX-1.1	Controlled Equity OfferingSM Sales Agreement, dated July 6, 2018, by and between Anavex Life Sciences Corp. and Cantor Fitzgerald & Co. (incorporated by reference to our Current Report on Form 8-K filed on July 6, 2018) Exhibit 1.1 ANAVEX LIFE SCIENCES CORP. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement July 6, 2018 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Anavex Life Sciences Corp., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows: 1. Iss
July 6, 2018	424B5	Anavex Life Sciences Corp. Up to $50,000,000 Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated September 6, 2016) Registration No.
May 10, 2018	10-Q	AVXL / Anavex Life Sciences Corp. 10-Q (Quarterly Report) 10-Q 1 s11004510q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Nu
April 20, 2018	8-K	Submission of Matters to a Vote of Security Holders 8-K 1 s1097348k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2018 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Comm
March 8, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2018 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of i
March 8, 2018	EX-99.1	Anavex Life Sciences Strengthens Management Team and Board of Directors Company Appoints Stephan Toutain as Senior Vice President of Operations and Claus van der Velden to Board of Directors Exhibit 99.1 Anavex Life Sciences Strengthens Management Team and Board of Directors Company Appoints Stephan Toutain as Senior Vice President of Operations and Claus van der Velden to Board of Directors New York — March 5, 2018 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatmen
March 8, 2018	DEF 14A	AVXL / Anavex Life Sciences Corp. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, For Use of
February 14, 2018	SC 13G/A	AVXL / Anavex Life Sciences Corp. / Park West Asset Management LLC - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ANAVEX LIFE SCIENCES CORP. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 032797300 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
February 7, 2018	10-Q	AVXL / Anavex Life Sciences Corp. 10-Q (Quarterly Report) 10-Q 1 s10893510q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File
December 11, 2017	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☐ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37606 ANAVEX LIFE SCIE
December 11, 2017	EX-10.7	Amended and Restated Employment Agreement by and between the Company and with Sandra Boenisch (incorporated by reference to our Annual Report on Form 10-K filed on December 11, 2017) Exhibit 10.7 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT, dated October 4, 2017 with an effective date of October 1, 2017 (the ?Agreement?), is by and between Anavex Life Sciences Corp. (the ?Company? or ?Anavex?), and Sandra Boenisch (the ?Employee?). The Company and the Employee are referred to each individually as a ?Party? and collectively as the ?P
December 11, 2017	EX-99.1	Insider Trading Policy Adopted August 9, 2017 (incorporated by reference to our Annual Report on Form 10-K filed on December 11, 2017) Exhibit 99.1 ANAVEX LIFE SCIENCES CORP. Insider Trading Policy Anavex Life Sciences Corp. (?Anavex?) has adopted this Insider Trading Policy (the ?Policy?) to promote compliance with federal securities laws by directors, officers, employees and consultants of Anavex and its affiliates, as well as any immediate family members sharing the household of any of the foregoing (collectively, the ?Covered
December 11, 2017	EX-21.1	SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Incorporation or Organization Anavex Australia Pty Limited Australia Anavex Germany GmbH Germany Anavex Canada Ltd. Ontario, Canada
October 6, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 s1077088k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2017 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 98-0608404 (State or other jurisdiction (Com
September 7, 2017	424B3	Anavex Life Sciences Corp. 5,000,000 Shares of Common Stock Offered by a Selling Security Holder 424B3 1 s107410424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-218292 Anavex Life Sciences Corp. 5,000,000 Shares of Common Stock Offered by a Selling Security Holder This prospectus relates to the sale by Lincoln Park Capital Fund, LLC, or Lincoln Park, of up to 5,000,000 shares of the common Stock, par value $0.001 per share of Anavex Life Sciences Corp., a Nevada corporati
August 11, 2017	S-8	Anavex Life Sciences S-8 As filed with the Securities and Exchange Commission on August 11, 2017 Registration No.
August 7, 2017	10-Q	Quarterly Report - 10-Q 10-Q 1 s10702910q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Num
June 9, 2017	LETTER	LETTER Mail Stop 3561 June 9, 2017 Via E-mail Christopher Missling, PhD Chief Executive Officer Anavex Life Sciences Corp.
June 9, 2017	CORRESP	Anavex Life Sciences ESP CORRESP 1 filename1.htm ANAVEX LIFE SCIENCES CORP. 51 W. 52nd Street, 7th Floor New York, NY 10019-6163 June 9, 2017 VIA EDGAR United States Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Attn: Hillary Daniels Re: Anavex Life Sciences Corp. Request for Acceleration of Registration Statement on Form S-3 File No. 333-218292 Ladies and Gentlemen: Pursuant to Rule 461 unde
May 26, 2017	S-3	Anavex Life Sciences S-3 As filed with the Securities and Exchange Commission on May 26, 2017 Registration No.
May 10, 2017	EX-99.1	Corporate Investment Policy Adopted May 4, 2017 (incorporated by reference to our Quarterly Report on Form 10-Q filed on May 10, 2017) Exhibit 99.1 ANAVEX LIFE SCIENCES CORP. Investment Policy & Guidelines Purpose: The purpose of this policy is to set forth the guidelines for managing the available cash of Anavex Life Sciences Corp. by its designated money managers. The funds are to be invested to assure preservation of capital, liquidity, and security of corporate funds while providing a reasonable return of investment. Objectiv
May 10, 2017	10-Q	Quarterly Report - QUARTERLY REPORT 10-Q 1 s10608510q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2017 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commis
April 21, 2017	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2017 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 98-0608404 (State or other jurisdiction (Commission (IRS Employer of
March 17, 2017	EX-99.1	Certificate of Amendment (PURSUANT TO NRS 78.385 AND 78.390) Exhibit 99.1 BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Certificate of Amendment (PURSUANT TO NRS 78.385 AND 78.390) USE BLACK INK ONLY ? DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Articles of Incorporation For Nevada Profit Corporations (Pursuant to NRS 78.385 and 78.390 -
March 17, 2017	DEFA14A	Anavex Life Sciences DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of
March 10, 2017	DEF 14A	Anavex Life Sciences DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of
February 27, 2017	EX-99	EX-99 Exhibit A
February 27, 2017	PRE 14A	Anavex Life Sciences PRE 14A PRE 14A 1 s105424pre14a.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: þ Preliminary Proxy
February 13, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2017 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 98-0608404 (State or other jurisdiction (Commission (IRS Employer o
February 13, 2017	EX-99.1	Anavex Life Sciences Strengthens Board of Directors Exhibit 99.1 Anavex Life Sciences Strengthens Board of Directors NEW YORK ? February 13, 2017 ? Anavex Life Sciences Corp. (?Anavex? or the ?Company?) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer?s disease, other central nervous system (CNS) diseases, pain
February 13, 2017	SC 13G	AVXL / Anavex Life Sciences Corp. / Park West Asset Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ANAVEX LIFE SCIENCES CORP. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 032797300 (CUSIP Number) February 1, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
February 7, 2017	10-Q	Quarterly Report - 10-Q 10-Q 1 s10522210q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File
December 14, 2016	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-51652 ANAVEX LIFE SCIE
December 14, 2016	EX-14.1	Code of Ethics Adopted on September 13, 2016 (incorporated by reference to our Annual Report on Form 10-K filed on December 14, 2016) Exhibit 14.1 BUSINESS CODE OF CONDUCT & ETHICS I. Purpose As a business engaged in the discovery, development and commercialization of medicines for the treatment of various diseases, AnavexTM Life Sciences Corp. (the ?Anavex? or the ?Company?) must always act in a way that reflects the highest standards of corporate behavior. Each of us must always exercise good judgment and common sense in makin
October 21, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2016 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 98-0608404 (State or other jurisdiction (Commission (IRS Employer o
October 21, 2016	EX-99.1	Christopher U. Missling, MS, PhD, MBA, President and CEO of Anavex Life Sciences Corp. Exhibit 99.1 Christopher U. Missling, MS, PhD, MBA, President and CEO of Anavex Life Sciences Corp. Dr. Missling, President and CEO of Anavex, has over 20 years of healthcare industry experience within large pharmaceutical companies, the biotech industry and investment banking. Prior to joining Anavex, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sa
September 12, 2016	424B3	Anavex Life Sciences Corp. $100,000,000 of Shares of Common Stock and Warrants 6,754,609 Shares of Common Stock Offered by Selling Security Holder 424B3 1 s104089424b3.htm 424B3 PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-207600 Anavex Life Sciences Corp. $100,000,000 of Shares of Common Stock and Warrants 6,754,609 Shares of Common Stock Offered by Selling Security Holder Anavex Life Sciences Corp., a Nevada corporation (“us”, “we”, “our”, “Anavex” or the “Company”) may offer and sell from time to time, in one or more s
September 1, 2016	CORRESP	Anavex Life Sciences ESP ANAVEX LIFE SCIENCES CORP. 51 W. 52nd Street, 7th Floor New York, NY 10019-6163 September 1, 2016 VIA EDGAR Mr. John Reynolds Assistant Director United States Securities and Exchange Commission 100 F. Street, N.E. Mail Stop 3561 Washington, DC 20549 Re: Anavex Life Sciences Corp. Request for Acceleration of Registration Statement on Form S-3 Initially Filed October 26, 2015 File No. 333-207600 Dea
August 31, 2016	S-3/A	Anavex Life Sciences S-3/A As filed with the Securities and Exchange Commission on August 31, 2016 Registration No.
August 30, 2016	CORRESP	Anavex Life Sciences ESP CORRESP 1 filename1.htm Anavex Life Sciences Corp. 51 West 52nd Street, 7th Floor New York, NY 10019-6163 August 30, 2016 John Reynolds Assistant Director United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Tel: (202) 551-3715 Re: Anavex Life Sciences Corp. Amendment No. 2 to Registration Statement on Form S-3 Filed August 26, 20
August 30, 2016	LETTER	LETTER Mail Stop 3561 August 30, 2016 Christopher Missling, PhD Chief Executive Officer Anavex Life Sciences Corp.
August 26, 2016	S-3/A	Anavex Life Sciences S-3/A As filed with the Securities and Exchange Commission on August 26, 2016 Registration No.
August 26, 2016	CORRESP	Anavex Life Sciences ESP ANAVEX LIFE SCIENCES CORP. 51 West 52nd Street, 7th Floor New York, New York 10019-6163 August 26, 2016 VIA EDGAR John Reynolds, Assistant Director United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Tel: (202) 551-3715 Re: Anavex Life Sciences Corp. Registration Statement on Form S-3 Filed October 26, 2015, as Amended on August
August 25, 2016	LETTER	LETTER Mail Stop 3561 August 25, 2016 Christopher Missling, PhD Chief Executive Officer Anavex Life Sciences Corp.
August 18, 2016	EX-10.2	REGISTRATION RIGHTS AGREEMENT Anavex Life Sciences Corp.: Exhibit 10.2 - Filed by newsfilecorp.com Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of October 21, 2015, by and between ANAVEX LIFE SCIENCES CORP., a Nevada corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the ?Buyer?). Ca
August 18, 2016	S-3/A	Anavex Life Sciences S-3/A As filed with the Securities and Exchange Commission on August 18, 2016 Registration No.
August 18, 2016	EX-10.1	PURCHASE AGREEMENT Anavex Life Sciences Corp.: Exhibit 10.1 - Filed by newsfilecorp.com Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the ?Agreement?), dated as of October 21, 2015, by and between ANAVEX LIFE SCIENCES CORP., a Nevada corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the ?Investor?). WHEREAS: Subject to the terms and conditions set fort
August 18, 2016	CORRESP	Anavex Life Sciences ESP ANAVEX LIFE SCIENCES CORP. 51 West 52nd Street, 7th Floor New York, New York 10019-6163 August 18, 2016 VIA EDGAR John Reynolds, Assistant Director United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Tel: (202) 551-3715 Re: Anavex Life Sciences Corp. Registration Statement on Form S-3 Filed October 26, 2015 File No. 333-207600 De
August 11, 2016	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51652 ANAVEX LIFE
July 22, 2016	EX-10.1	Amended and Restated First Amendment to Employment Agreement, dated as of July 18, 2016, by and between the Company and Christopher Missling, PhD (incorporated by reference to our Current Report on Form 8-K filed on July 22, 2016) Exhibit 10.1 AMENDED AND RESTATED FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This Amended and Restated First Amendment to Employment Agreement (the ?Amendment?) is executed on this 18th day of July 2016, and made effective as defined below (the ?Effective Date?), by and between Christopher Missling, PhD (hereinafter referred to as ?Executive?) and Anavex Life Sciences Corp. (?Employer? and, together
July 22, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2016 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 98-0608404 (State or other jurisdiction (Commission (IRS Employer of i
July 7, 2016	EX-10.1	First Amendment to Employment Agreement, dated as of July 5, 2016, by and between the Company and Christopher Missling, PhD (incorporated by reference to our Current Report on Form 8-K filed on July 7, 2016) Exhibit 10.1 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (the ?Amendment?) is executed on this 5th day of July 2016 (the ?Effective Date?), by and between Christopher Missling, PhD (hereinafter referred to as ?Executive?) and Anavex Life Sciences Corp. (?Employer? and, together with its subsidiaries, the ?Company?) and serves to amend that certain Employmen
July 7, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 s1036668k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2016 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 20-8365999 (State or other jurisdiction (C
June 23, 2016	EX-99.2	Anavex to Present at the 2016 Rett Syndrome Symposium Exhibit 99.2 Anavex to Present at the 2016 Rett Syndrome Symposium NEW YORK – June 23, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain an
June 23, 2016	EX-99.1	EX-99.1 Exhibit 99.1
June 23, 2016	8-K	Anavex Life Sciences 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2016 Anavex Life Sciences Corp. (Exact name of registrant as specified in its charter) Nevada 000-51652 98-0608404 (State or other jurisdiction (Commission (IRS Employer of i
May 11, 2016	10-Q	Quarterly Report - FORM 10-Q 10-Q 1 s10319910q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission Fi
May 10, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2016 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 98-0608404 (State or other jurisdiction (Commission (IRS Employer of inc
May 6, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2016 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 98-0608404 (State or other jurisdiction (Commission (IRS Employer of inc
May 6, 2016	EX-99.1	EX-99.1 Exhibit 99.1
April 1, 2016	DEF 14A	Anavex Life Sciences DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of
February 16, 2016	SC 13G	AVXL / Anavex Life Sciences Corp. / DAFNA Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* ANAVEX LIFE SCIENCES CORP. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class Securities) 032797102 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r

DE:12X1	2,17 €
GB:0HFR	2,63 $

AVXL / Anavex Life Sciences Corp. - SEC-Einreichungen, Jahresbericht, Proxy Statement

Basisstatistiken

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?

Other Listings